ATEC

Business Context and Reporting Period

Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: Alphatec designs, develops, manufactures, and markets products for the surgical treatment of spine disorders. Operations are conducted primarily in the United States and Japan (via Alphatec Pacific). The company focuses on spinal implant products including screws, spacers, and plates.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Data derived from Condensed Consolidated Financial Statements.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 17.1% ($3.0 million) for the quarter and 7.1% ($3.9 million) for the nine months compared to the prior year periods. U.S. sales drove the increase, while Asia sales declined year-over-year due to reduced non-spine revenue, partially offset by the Japan Ortho Medical acquisition.
• Profitability: The company remains unprofitable. Net loss for the nine months ended September 30, 2007, was $9.0 million, an improvement from the $14.5 million loss in the same period in 2006. This improvement was driven by reduced excess inventory charges and lower general and administrative expenses.
• Operating Expenses:
  • R&D: Increased 31.5% for the quarter due to added personnel and consulting.
  • In-Process R&D (IPR&D): A significant non-cash charge of $2.3 million was recorded in Q3 2007 for the acquisition of the GLIF system license.
  • Sales & Marketing: Decreased 12.6% for the quarter due to reduced compensation and travel expenses.
  • G&A: Decreased 21.2% for the nine months, largely due to the absence of a $1.6 million IPO bonus recognized in 2006 and a $2.4 million favorable severance settlement.
• Acquisitions: Acquired Japan Ortho Medical (formerly Blues Medica Japan) on May 1, 2007, for a total purchase price of $2.5 million, enhancing distribution in Japan.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: The company raised approximately $32.2 million in net proceeds from a public offering of 10 million shares in September 2007. Management believes current cash, combined with operating revenues and credit facilities, is sufficient to fund operations through 2008.
• Debt Facilities: On October 2, 2007 (post-period end), the company replaced its Bank of the West line of credit with a new $20.0 million Credit Agreement with Merrill Lynch. As of September 30, 2007, the company had $2.7 million outstanding on a Japanese credit facility.
• Unusual Items:
  • IPR&D Charges: Recorded $2.3 million for the GLIF system license in Q3. A further $5.0 million charge for the V-Stent vertebroplasty technology license is expected in Q4 2007.
  • Stock-Based Compensation: Recorded a credit of $0.3 million for the nine months ended September 30, 2007, due to adjustments in forfeiture rates and settlements with terminated executives.
  • Restructuring: Announced a cost-reduction plan in August 2007 eliminating 9% of positions, resulting in a $0.4 million severance charge in Q3.
• Risks and Contingencies:
  • Patent Litigation: Involved in patent infringement litigation with Biedermann Motech GmbH and DePuy Spine, Inc. regarding the "678 Patent." An adverse outcome could materially affect the business as the accused products (Zodiac and Solanas) represent a significant portion of revenue.
  • Breach of Contract: Litigation pending with four surgeons claiming royalties on polyaxial screws. The company intends to defend vigorously.
  • Regulatory: Commercialization of new technologies (GLIF, V-Stent) is subject to regulatory approvals and clinical trial success.

Investor Verification Checklist

• Patent Litigation Status: Verify the current status of the DePuy/Biedermann patent infringement suit and the impact of the recent reexamination of the 678 Patent on the Zodiac and Solanas product lines.
• Future IPR&D Charges: Confirm the timing and accounting treatment of the anticipated $5.0 million charge for the V-Stent license in Q4 2007.
• Debt Covenants: Review the specific covenants of the new $20.0 million Merrill Lynch Credit Agreement entered into in October 2007 to ensure compliance with financial ratios.
• Inventory Valuation: Assess the adequacy of the reserve for excess and obsolete inventory, which totaled $10.1 million as of September 30, 2007.
• Japan Operations: Evaluate the performance of the newly acquired Japan Ortho Medical and the strategic alliance with Noas Medical Company.